Zynerba Pharmaceuticals Net Tangible Assets

Zynerba Pharmaceuticals (ZYNE) currently reports a net tangible assets of $29M as of June 2023. That compares with $57M in the prior-year period — down 49.3% year over year. Use the charts on this page to explore Zynerba Pharmaceuticals's net tangible assets history and peer comparisons.

Zynerba Pharmaceuticals's net tangible assets decreased from $57M to $29M — a 49.3% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zynerba Pharmaceuticals reported $29M in net tangible assets as of June 2023. That compares with $57M in the prior-year period — down 49.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zynerba Pharmaceuticals, and consider following ZYNE for alerts when major investors trade the stock.

Zynerba Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZYNE with unrelated industries.